Sedatives and sleeping pills: Benzodiazepines, barbiturates and new sleeping pills. Clinical pharmacology of alcohol and its antagonists. Elaborate detailed ppt content
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
Running Command
Your presentation is ready (503 KB, 16x9 format, dark navy theme with colour-coded sections):
Sedatives Sleeping Pills Alcohol Pharmacology
Presentation · PPTX
What's Inside — 20 Slides Across 5 Sections
Section A — Benzodiazepines (cyan accent)
| Slide | Content |
|---|---|
| Mechanism of Action | GABA-A allosteric site, α-subunit selectivity, frequency of Cl⁻ opening, contrast with barbiturates |
| Pharmacokinetics | Absorption, LOT rule, half-life classification (ultra-short to long), special populations |
| Clinical Uses (2-column) | Full indications table + key drug examples (diazepam, lorazepam, midazolam, clonazepam…) |
| Adverse Effects & Toxicity | CNS effects, tolerance/dependence, withdrawal seizures, overdose management |
| Flumazenil | Mechanism, PK, uses, cautions (seizure precipitation, TCA overdose warning) |
Section B — Barbiturates (amber accent)
| Slide | Content |
|---|---|
| Mechanism | Duration of Cl⁻ opening, direct GABA activation at high doses, AMPA blockade, RAS depression |
| Classification Table | Ultra-short / Short / Intermediate / Long-acting with drugs and uses |
| Pharmacokinetics & Drug Interactions | CYP induction (1A2, 2C9, 2C19, 3A4), porphyria risk, enzyme auto-induction |
| Overdose | Fatal dose thresholds, respiratory depression mechanism, management (no antidote; urine alkalinisation) |
| Withdrawal | Timeline, grand mal seizures, DTs-like syndrome, management strategy |
Section C — New Sleeping Pills (green accent)
| Slide | Content |
|---|---|
| Z-Drugs | α1 selectivity, zolpidem/zaleplon/eszopiclone PK, complex sleep behaviours |
| 2-Column: Melatonin Agonists vs Orexin Antagonists | Ramelteon/tasimelteon vs suvorexant/lemborexant with mechanisms and clinical notes |
| Comparison Table | All 5 drug classes side-by-side (receptor, mechanism, key notes) |
Section D — Alcohol Pharmacology (coral accent)
| Slide | Content |
|---|---|
| Pharmacokinetics | 3 metabolic pathways (ADH, catalase, MEOS/CYP2E1), zero-order kinetics, acetaldehyde metabolism |
| CNS Effects & BAC | mg/dL correlation table (30 → 400), GABA-A/NMDA/opioid/dopamine mechanisms |
| Chronic Toxicity | Wernicke-Korsakoff, hepatic progression, cardiomyopathy, holiday heart |
| Withdrawal Syndrome | NMDA hyperactivity pathophysiology, CIWA timeline (6 h → 72 h DTs), treatment |
Section E — Alcohol Antagonists (cyan accent)
| Slide | Content |
|---|---|
| Disulfiram | Irreversible ALDH inhibition, DER at different BAC levels, drug interactions |
| Naltrexone vs Acamprosate (2-column) | Mechanisms, dosing, efficacy evidence, contraindications |
| Other Agents | Baclofen, nalmefene, gabapentin; full pharmacotherapy strategy |
| Drug Comparison Table | Disulfiram / Naltrexone / Acamprosate / Baclofen side-by-side |
Sources used: Goodman & Gilman 14e, Katzung 16e, Adams & Victor's Neurology 12e, Lippincott Pharmacology, Kaplan & Sadock Psychiatry.
This is a shared conversation. Sign in to Orris to start your own chat.